Stemline Therapeutics Inc. (STML) Sees Large Volume Increase
Shares of Stemline Therapeutics Inc. (NASDAQ:STML) saw unusually-strong trading volume on Wednesday . Approximately 362,384 shares traded hands during mid-day trading, an increase of 136% from the previous session’s volume of 153,507 shares.The stock last traded at $8.20 and had previously closed at $7.69.
Several research analysts recently commented on STML shares. Jefferies Group reaffirmed a “buy” rating and issued a $23.00 target price on shares of Stemline Therapeutics in a research report on Friday, July 22nd. Roth Capital reaffirmed a “buy” rating and issued a $32.00 target price on shares of Stemline Therapeutics in a research report on Tuesday, May 10th. Wedbush reaffirmed an “outperform” rating and issued a $15.00 target price on shares of Stemline Therapeutics in a research report on Tuesday. Finally, Zacks Investment Research raised Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research report on Wednesday, July 6th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $19.31.
The stock has a 50-day moving average of $7.35 and a 200-day moving average of $6.16. The company’s market capitalization is $144.47 million.
Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.03. Equities research analysts anticipate that Stemline Therapeutics Inc. will post ($2.11) EPS for the current fiscal year.
A hedge fund recently raised its stake in Stemline Therapeutics stock. Royce & Associates LLC raised its position in Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned about 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent filing with the SEC.
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.